VVOS News and Press, Vivos Therapeutics Inc. From 08/23/21

Trillium Therapeutics (NASDAQ:TRIL) +191% after acquisition by Pfizer for $2.3B Vivos Therapeutics (NASDAQ:VVOS) +61% on FDA 510k clearance for sleep apnea treatment device Xeris Pharmaceuticals (NASDAQ:XERS) +48% announces approval of supplemental new drug Application (sN...

Part of the Vivos System Treatment, the mmRNA Device Represents a Highly Effective Non-Surgical, Non-Invasive and Non-Pharmaceutical Alternative for Patients Suffering from OSA Approval Expands Insurance Reimbursement Potential, Including the Opportunity for Medicare Coverage fo...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has rel...

HIGHLANDS RANCH, Colo., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients s...

According to a new study , people who spend less time watching TV and are physically active face a diminished risk of suffering from obstructive sleep apnea. This is the first research to examine sedentary lifestyles as well as physical activity with respect to the risk of developing obstru...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has ann...

Vivos Therapeutics, Inc. (VVOS) Q2 2021 Earnings Conference Call August 12, 2021 05:00 PM ET Company Participants Edward Loew - Investor Relations Officer Kirk Huntsman - Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capita...

Vivos Therapeutics (NASDAQ:VVOS): Q2 GAAP EPS of -$0.19 misses by $0.01. Revenue of $4.5M beats by $0.9M. Press Release For further details see: Vivos Therapeutics EPS misses by $0.01, beats on revenue

Second Quarter Revenue Increased Over 37% Year-Over-Year and 30% Over Q1 2021 Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS) , a medica...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), will pa...